Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-masked, placebo-controlled, cross-over, 32 weeks study
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Infliximab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 26 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association.
- 22 Apr 2010 Results published in Diabetes Care.
- 19 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.